Month: January 2024

“Seat 16” program allows audiences to share the critically acclaimed film with teens across the country SUNNYVALE, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, announced a month-long initiative to amplify Ava DuVernay’s new film ORIGIN and the film’s groundbreaking Seat16 program. Seat16 allows anyone to gift $16 or more to purchase an ORIGIN movie ticket for a young person who might not otherwise be able to purchase a ticket to the film. For 23 days, 23andMe will donate 100 seats daily to support the program. ARRAY, the multi-platform arts and social impact collective founded by Ava DuVernay, created the Seat16 initiative to ensure that 10,000 young people across the nation get to experience ORIGIN. Written, directed, and produced by...

Check Point’s latest innovation, brings AI-powered efficiency and collaboration to cyber security management across platforms BANGKOK, Thailand, Jan. 30, 2024 (GLOBE NEWSWIRE) — Check Point Software Technologies Ltd. (NASDAQ: CHKP), a leading AI-powered, cloud-delivered cyber security platform provider, today announced the launch of the first-generation Infinity AI Copilot. Leveraging the convergence of AI and cloud technologies, Infinity AI Copilot addresses the growing global shortage of cyber security practitioners by boosting the efficiency and effectiveness of security teams. “With Infinity AI Copilot, we are ushering in a new era of cyber security where human-machine collaboration takes center stage,” said Eyal Manor, VP of Product Management at Check Point Software Technologies. “Our vision is to enable security...

         NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the second quarter ended December 31, 2023. Mesoblast Chief Executive Silviu Itescu said: “It has been a very busy quarter in which we have made substantial operational progress across our three lead Phase 3 assets. We have generated significant new potency and characterization data for our lead product Ryoncil® (remestemcel-L) for children with acute GVHD, as requested by FDA, and will submit these data ahead of our planned meeting with FDA this quarter.” “Our second Phase 3 back pain trial with rexlemestrocel-L, aiming to confirm the durable pain reduction that was seen in the first Phase 3 trial, is underway. Finally, we were...

EDMONTON, Alberta, Jan. 30, 2024 (GLOBE NEWSWIRE) — Regenx Tech Corp. (the “Company” or “Regenx”) (CSE: RGX) (OTCQB: RGXTF) (FSE: YRS WKN:A2DSW3) announces that it has revised the previously announced unsecured and non-brokered Convertible Debenture Financing (“Offering”) for gross proceeds of $1,700,401.73. The Debentures will bear interest at the rate of fifteen percent (15%) per annum, payable on the maturity date and will mature on December 31, 2025. The Debentures will be convertible at the holder’s option into common shares of the Corporation (“Common Shares”) at a conversion price of: (i) $0.05 per Common Share until the date that is one (1) year from the closing date; and (ii) $0.105 per Common Share for the period from the date following one (1) year from the closing date until the maturity date....

VANCOUVER, British Columbia, Jan. 30, 2024 (GLOBE NEWSWIRE) — Osino Resources Corp. (TSXV:OSI) (NSX:OSN) (FSE:RSR1) (OTCQX:OSIIF) (“Osino” or the “Company“) is pleased to announce that the Supreme Court of British Columbia (the “Court”) has issued an interim order (the “Interim Order”) in connection with the previously announced plan of arrangement (the “Plan of Arrangement”) under the Business Corporations Act (British Columbia), pursuant to which Dundee Precious Metals Inc. (“DPM”) will acquire all of the issued and outstanding common shares of Osino (the “Arrangement”). For further information on the Arrangement and the definitive arrangement agreement between Osino and DPM (the “Arrangement Agreement”), please refer to the joint news release of the parties dated December 18, 2023. Interim Order The Interim...

NORWOOD, Mass., Jan. 30, 2024 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced that it plans to offer and sell shares of its common stock or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock in an underwritten registered public offering. All of the securities in the offering are to be sold by Corbus. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Corbus intends to use the net proceeds of the proposed underwritten offering to fund the clinical development of its pipeline and for working capital and other general corporate purposes. Jefferies...

CALGARY, Alberta, Jan. 30, 2024 (GLOBE NEWSWIRE) — Wilmington Capital Management Inc. (“Wilmington” or the “Corporation”) is pleased to announce that its Board of Directors has determined that the embedded value of Wilmington’s marinas investment, including Maple Leaf Marinas Limited Partnership (“MLM”), has been substantially realized. As a result, the Corporation will seek to effect a sale of its approximate 17.32% interest therein (along with its corresponding general partner interest) in accordance with the MLM limited partnership agreement. Subject to applicable laws and after giving consideration to its ongoing liquidity needs, the Corporation anticipates that it will effect a distribution to its shareholders out of proceeds received in connection with any such sale. Executive Officers of the Corporation are available at...

HOUSTON, TEXAS, Jan. 30, 2024 (GLOBE NEWSWIRE) — Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”) announced today that it has signed an equity purchase agreement to sell its Activ Nutritional, LLC subsidiary, which owns the Viactiv® brand and business, to Doctor’s Best Inc. (“Doctor’s Best”), a wholly-owned subsidiary of Kingdomway USA Corp. (“Kingdomway”), for gross cash consideration of $17.2 million, payable in full at closing. The transaction has been approved by the respective Boards of Directors of Guardion and of Doctor’s Best, and remains subject to normal and customary closing conditions, including approval of the transaction by the Company’s stockholders at a forthcoming Special Meeting of Stockholders. Assuming requisite approval by the Company’s stockholders, the transaction is expected to...